Exelixis (NASDAQ:EXEL) initiates a
Phase 3 clinical trial, CONTACT-01, evaluating the combination of
Cabometyx (cabozantinib) and Roche’s Tecentriq (atezolizumab) in
patients with metastatic non-small cell lung cancer who have been
previously treated with an immune checkpoint inhibitor nd platinum-based
chemo.
The primary endpoint of the 350-subject study is overall survival.
The company plans two additional Phase 3s, in
metastatic castration-resistant prostate cancer and renal cell
carcinoma, under its clinical trial collaboration with Roche.
https://seekingalpha.com/news/3582292-exelixis-launches-late-stage-study-of-cabometyx-combo-in-lung-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.